ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (Nasdaq: BSMD), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors, and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy, today announced that the Company has shipped its first order of Embosphere® Microspheres to the People’s Republic of China. In January 2008, China’s Medical Device Department of the State Food and Drug Administration approved the Company’s Embosphere Microspheres for clinical use for vascular embolizations, arteriovenous malformations, hypervascularized tumors, and symptomatic uterine fibroids.
